DN 1417 | CAS#77026-81-4 | thyrotropin releasing hormone analog

MedKoo Cat#: 597823 | Name: DN 1417

Description:

WARNING: This product is for research use only, not for human or veterinary use.

DN 1417 is a thyrotropin releasing hormone analog.

Chemical Structure

DN 1417

CAS#77026-81-4

Theoretical Analysis

MedKoo Cat#: 597823

Name: DN 1417

CAS#: 77026-81-4

Chemical Formula: C22H29N5O12

Exact Mass:

Molecular Weight: 555.49

Elemental Analysis: C, 47.57; H, 5.26; N, 12.61; O, 34.56

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

DN 1417; DN-1417; DN1417;

IUPAC/Chemical Name

(2S)-1-((5-oxotetrahydrofuran-2-carbonyl)-L-histidyl)pyrrolidine-2-carboxamide 2-hydroxypropane-1,2,3-tricarboxylate

InChi Key

YYPBZNVNEDBLON-MEMPEZCVSA-N

InChi Code

InChI=1S/C16H21N5O5.C6H8O7/c17-14(23)11-2-1-5-21(11)16(25)10(6-9-7-18-8-19-9)20-15(24)12-3-4-13(22)26-12;7-3(8)1-6(13,5(11)12)2-4(9)10/h7-8,10-12H,1-6H2,(H2,17,23)(H,18,19)(H,20,24);13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)/t10-,11-,12?;/m0./s1

SMILES Code

O=C(N)[C@H]1N(C([C@H](CC2=CNC=N2)NC(C(CC3)OC3=O)=O)=O)CCC1.O=C(CC(C(O)=O)(O)CC(O)=O)O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 555.49 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Nakahara T, Matsumoto T, Hirano M, Uchimura H, Yokoo H, Nakamura K, Ishibashi K, Hirano H. Effect of DN-1417, a thyrotropin releasing hormone analog, on dopaminergic neurons in rat brain. Peptides. 1985 Nov-Dec;6(6):1093-9. PubMed PMID: 3938840. 2: Oshima I, Saito S, Shiota K, Miyake A, Oka Y, Nakayama R. Kinetic study on disappearance of gamma-butyrolactone-gamma-carbonyl-L-histidyl-L-prolinamide (DN-1417) from plasma using a radioimmunoassay for DN-1417 isobutylamide. J Pharmacobiodyn. 1983 Mar;6(3):202-8. PubMed PMID: 6410041. 3: Mori N, Fukatsu T. Anticonvulsant effect of DN-1417, a derivative of thyrotropin-releasing hormone, and liposome-entrapped DN-1417, on amygdaloid-kindled rats. Epilepsia. 1992 Nov-Dec;33(6):994-1000. PubMed PMID: 1464282. 4: Sakai S, Baba H, Sato M, Wada JA. Effect of DN-1417 on photosensitivity and cortically kindled seizure in Senegalese baboons, Papio papio. Epilepsia. 1991 Jan-Feb;32(1):16-21. PubMed PMID: 1898719. 5: Hawley RJ, Kratz R, Goodman RR, McCutchen CB, Sirdofsky M, Hanson PA. Treatment of amyotrophic lateral sclerosis with the TRH analog DN-1417. Neurology. 1987 Apr;37(4):715-7. PubMed PMID: 3104820. 6: Mizuki Y, Ushijima I, Yamada M, Tanaka M, Inanaga K. A treatment trial with an analog of thyrotropin-releasing hormone (DN-1417) and des-tyrosine-gamma-endorphin in schizophrenia. Int Clin Psychopharmacol. 1986 Oct;1(4):303-13. PubMed PMID: 2881964. 7: Nagai Y, Narumi S, Saji Y, Nagawa Y. [A TRH analog (DN-1417). Antagonistic effects on reserpine-induced decreases in local cerebral glucose utilization and cerebral monoamine levels]. Nihon Yakurigaku Zasshi. 1985 May;85(5):315-26. Japanese. PubMed PMID: 3928465. 8: Nagai Y, Narumi S, Miyamoto M, Shima T, Saji Y, Nagawa Y. [A TRH analog (DN-1417). Effects on the levels of monoamines and the metabolites in the various brain regions in rats]. Nihon Yakurigaku Zasshi. 1985 Apr;85(4):209-20. Japanese. PubMed PMID: 3924795. 9: Ogawa T, Moriwake T, Morimoto K, Sato M, Otsuki S. [The effect of a novel TRH analog (DN-1417) on postictal seizure inhibition in amygdaloid kindled cats]. No To Shinkei. 1984 Oct;36(10):951-5. Japanese. PubMed PMID: 6440585. 10: Yokoo H, Nakahara T, Matsumoto T, Inanaga K, Uchimura H. Effect of TRH analog (DN-1417) on tyrosine hydroxylase activity in mesocortical, mesolimbic and nigrostriatal dopaminergic neurons of rat brain. Peptides. 1987 Jan-Feb;8(1):49-53. PubMed PMID: 2883633. 11: Nakamura J, Mukasa H, Hashimoto M, Inanaga K. [Effect of the TRH analog DN-1417 on the appearance of frontal midline theta activity (Fm0)]. Yakubutsu Seishin Kodo. 1987 Jun;7(2):321-6. Japanese. PubMed PMID: 2891228. 12: Miyamoto M, Saji Y, Nagawa Y. [TRH and its analog (DN-1417). Effects on central dopaminergic system-dependent behaviors in rats and mice]. Nihon Yakurigaku Zasshi. 1985 Mar;85(3):129-41. Japanese. PubMed PMID: 3924793. 13: Ishii M, Igarashi M, Honda Y. Effect of TRH and DN-1417 on the vestibulo-ocular reflex in squirrel monkeys. Acta Otolaryngol Suppl. 1988;447:61-6. PubMed PMID: 3142205. 14: Nagai Y, Narumi S, Saji Y, Nagawa Y. [A TRH analog (DN-1417). Anti-reserpine action in electroconvulsive threshold and involvement of serotonergic (5-HT) mechanism in mice]. Nihon Yakurigaku Zasshi. 1985 Apr;85(4):221-30. Japanese. PubMed PMID: 3924796. 15: Miyamoto M, Nagai Y, Narumi S, Saji Y, Nagawa Y. TRH and its novel analog (DN-1417): antipentobarbital action and involvement of cholinergic mechanisms. Pharmacol Biochem Behav. 1982 Oct;17(4):797-806. PubMed PMID: 6817348. 16: Narumi S, Nagai Y, Saji Y, Nagawa Y. Increase in rat regional brain cyclic nucleotides by thyrotropin-releasing hormone (TRH) and its analog DN-1417. Jpn J Pharmacol. 1983 Oct;33(5):915-26. PubMed PMID: 6139495. 17: Bhargava HN, Matwyshyn GA. Comparative effects of thyrotropin releasing hormone, MK-771 and DN-1417 on morphine abstinence syndrome. Psychopharmacology (Berl). 1985;87(2):141-6. PubMed PMID: 2996045. 18: Inanaga K, Kumashiro H, Fukuyama Y, Ohtahara S, Shirouzu M. Clinical study of oral administration of DN-1417, a TRH analog, in patients with intractable epilepsy. Epilepsia. 1989 Jul-Aug;30(4):438-45. PubMed PMID: 2502385. 19: Shiota K, Miyake A, Tsunoda C, Oka Y, Nagawa Y, Nakayama R. Radioimmunoassay for an analog of thyrotrophin-releasing hormone, gamma-butyrolactone-gamma-carbonyl-L-histidyl-L-prolinamide (DN-1417). J Immunol Methods. 1982;51(1):69-80. PubMed PMID: 6809831. 20: Yamazaki N, Nagaoka A, Nagawa Y. [Effect of thyrotropin-releasing hormone (TRH) and its analog DN-1417 on scopolamine-induced impairment of short-term memory in rats]. Yakubutsu Seishin Kodo. 1986 Sep;6(3):359-66. Japanese. PubMed PMID: 3101313.